Trial Profile
A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2019
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 03 Aug 2019 Status changed from active, no longer recruiting to completed.
- 01 Dec 2006 New trial record.